Pure red cell aplasia caused by Parvovirus B19 infection in solid organ transplant recipients: A case report and review of literature

Duvuru Geetha, James B. Zachary, Helen M. Baldado, Joseph D. Kronz, Edward Kraus

Research output: Contribution to journalArticle

Abstract

Human Parvovirus B19 (PV B19) is one of the several recently described 'emerging viruses' and has been identified as the etiological agent of 'fifth disease' in childhood. Human PV B19, which is the etiological agent of transient erythroblastopenia in hemolytic anemia, is also a recognized rare cause of red cell aplasia in immunocompromised patients, including transplant recipients. To date, 26 cases of PV B19-induced red cell aplasia have been reported in solid organ transplant recipients. Twelve patients had cyclosporine-based immunosuppression and 14 had tacrolimus-based immunosuppression. Sixteen of these patients required treatment with commercial intravenous immunoglobulin alone, 1 required treatment with intravenous immunoglobulin and plasmapheresis, 4 required intravenous immunoglobulin and erythropoietin, 1 required treatment with intravenous immunoglobulin and conversion of tacrolimus to cyclosporine, 1 had improvement in hematocrit with erythropoietin alone and in 3 patients the disease was self-limiting. Herein, we report a case of pure red cell aplasia caused by acute PV B19 infection in a renal transplant recipient in whom the immunosuppressive regimen included prednisone, mycophenolate mofetil and tacrolimus and the red cell aplasia resolved with discontinuation of mycophenolate mofetil.

Original languageEnglish (US)
Pages (from-to)586-591
Number of pages6
JournalClinical Transplantation
Volume14
Issue number6
DOIs
StatePublished - 2000

Fingerprint

Pure Red-Cell Aplasia
Parvoviridae Infections
Intravenous Immunoglobulins
Tacrolimus
Human Parvovirus B19
Mycophenolic Acid
Transplants
Erythropoietin
Immunosuppression
Cyclosporine
Erythema Infectiosum
Parvovirus
Plasmapheresis
Hemolytic Anemia
Immunocompromised Host
Immunosuppressive Agents
Prednisone
Hematocrit
Therapeutics
Viruses

Keywords

  • Anemia
  • Immunoglobulin
  • Organ recipient
  • Parvovirus

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Pure red cell aplasia caused by Parvovirus B19 infection in solid organ transplant recipients : A case report and review of literature. / Geetha, Duvuru; Zachary, James B.; Baldado, Helen M.; Kronz, Joseph D.; Kraus, Edward.

In: Clinical Transplantation, Vol. 14, No. 6, 2000, p. 586-591.

Research output: Contribution to journalArticle

@article{b36abad571664b51ae0148fc73f46071,
title = "Pure red cell aplasia caused by Parvovirus B19 infection in solid organ transplant recipients: A case report and review of literature",
abstract = "Human Parvovirus B19 (PV B19) is one of the several recently described 'emerging viruses' and has been identified as the etiological agent of 'fifth disease' in childhood. Human PV B19, which is the etiological agent of transient erythroblastopenia in hemolytic anemia, is also a recognized rare cause of red cell aplasia in immunocompromised patients, including transplant recipients. To date, 26 cases of PV B19-induced red cell aplasia have been reported in solid organ transplant recipients. Twelve patients had cyclosporine-based immunosuppression and 14 had tacrolimus-based immunosuppression. Sixteen of these patients required treatment with commercial intravenous immunoglobulin alone, 1 required treatment with intravenous immunoglobulin and plasmapheresis, 4 required intravenous immunoglobulin and erythropoietin, 1 required treatment with intravenous immunoglobulin and conversion of tacrolimus to cyclosporine, 1 had improvement in hematocrit with erythropoietin alone and in 3 patients the disease was self-limiting. Herein, we report a case of pure red cell aplasia caused by acute PV B19 infection in a renal transplant recipient in whom the immunosuppressive regimen included prednisone, mycophenolate mofetil and tacrolimus and the red cell aplasia resolved with discontinuation of mycophenolate mofetil.",
keywords = "Anemia, Immunoglobulin, Organ recipient, Parvovirus",
author = "Duvuru Geetha and Zachary, {James B.} and Baldado, {Helen M.} and Kronz, {Joseph D.} and Edward Kraus",
year = "2000",
doi = "10.1034/j.1399-0012.2000.140612.x",
language = "English (US)",
volume = "14",
pages = "586--591",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Pure red cell aplasia caused by Parvovirus B19 infection in solid organ transplant recipients

T2 - A case report and review of literature

AU - Geetha, Duvuru

AU - Zachary, James B.

AU - Baldado, Helen M.

AU - Kronz, Joseph D.

AU - Kraus, Edward

PY - 2000

Y1 - 2000

N2 - Human Parvovirus B19 (PV B19) is one of the several recently described 'emerging viruses' and has been identified as the etiological agent of 'fifth disease' in childhood. Human PV B19, which is the etiological agent of transient erythroblastopenia in hemolytic anemia, is also a recognized rare cause of red cell aplasia in immunocompromised patients, including transplant recipients. To date, 26 cases of PV B19-induced red cell aplasia have been reported in solid organ transplant recipients. Twelve patients had cyclosporine-based immunosuppression and 14 had tacrolimus-based immunosuppression. Sixteen of these patients required treatment with commercial intravenous immunoglobulin alone, 1 required treatment with intravenous immunoglobulin and plasmapheresis, 4 required intravenous immunoglobulin and erythropoietin, 1 required treatment with intravenous immunoglobulin and conversion of tacrolimus to cyclosporine, 1 had improvement in hematocrit with erythropoietin alone and in 3 patients the disease was self-limiting. Herein, we report a case of pure red cell aplasia caused by acute PV B19 infection in a renal transplant recipient in whom the immunosuppressive regimen included prednisone, mycophenolate mofetil and tacrolimus and the red cell aplasia resolved with discontinuation of mycophenolate mofetil.

AB - Human Parvovirus B19 (PV B19) is one of the several recently described 'emerging viruses' and has been identified as the etiological agent of 'fifth disease' in childhood. Human PV B19, which is the etiological agent of transient erythroblastopenia in hemolytic anemia, is also a recognized rare cause of red cell aplasia in immunocompromised patients, including transplant recipients. To date, 26 cases of PV B19-induced red cell aplasia have been reported in solid organ transplant recipients. Twelve patients had cyclosporine-based immunosuppression and 14 had tacrolimus-based immunosuppression. Sixteen of these patients required treatment with commercial intravenous immunoglobulin alone, 1 required treatment with intravenous immunoglobulin and plasmapheresis, 4 required intravenous immunoglobulin and erythropoietin, 1 required treatment with intravenous immunoglobulin and conversion of tacrolimus to cyclosporine, 1 had improvement in hematocrit with erythropoietin alone and in 3 patients the disease was self-limiting. Herein, we report a case of pure red cell aplasia caused by acute PV B19 infection in a renal transplant recipient in whom the immunosuppressive regimen included prednisone, mycophenolate mofetil and tacrolimus and the red cell aplasia resolved with discontinuation of mycophenolate mofetil.

KW - Anemia

KW - Immunoglobulin

KW - Organ recipient

KW - Parvovirus

UR - http://www.scopus.com/inward/record.url?scp=0033652150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033652150&partnerID=8YFLogxK

U2 - 10.1034/j.1399-0012.2000.140612.x

DO - 10.1034/j.1399-0012.2000.140612.x

M3 - Article

C2 - 11127313

AN - SCOPUS:0033652150

VL - 14

SP - 586

EP - 591

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 6

ER -